Sehgal ANA, Tauber PA, Stieger RB, Kratzer B, et al. The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024. Int Arch Allergy Immunol 2023 Dec 12:1-15. doi: 10.1159/000533677.
PMID: 38086339